MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Overall, 597 of 630 patients were analyzable—247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for ...

MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast ...

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Median follow-up for recurrence was 9.2 years. Twenty-six ...

RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...

Please provide your email address to receive an email when new articles are posted on . Further study is needed to identify potential drivers of the association Low household income appeared ...

A risk score based on four factors — male sex, tumor size, World Health Organization (WHO) grade, and lymphovascular invasion — predicts recurrence in patients with node-negative pancreatic ...